AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17178490 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic surgery (lysis, lavage, and capsular stretch)
Number of subjects: 20
Study 15086603 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (12 patients; group A)
Number of subjects: 25
Study 15086603 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy (EIS) (13 patients; group B)
Number of subjects: 25
Study 11232676 — intervention group
Group type: COMPARATOR
Intervention: 1-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Number of subjects: 142
Study 11232676 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week treatment with lansoprazole (30 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxycillin (1 g b.i.d.)
Number of subjects: 142
Study 10921813 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 0
Study 10921813 — intervention group
Group type: COMPARATOR
Intervention: Pethidine
Number of subjects: 0
Study 8607560 — intervention group
Group type: EXPERIMENTAL
Intervention: FPANS 200 micrograms twice daily (bd)
Number of subjects: 549
Study 8607560 — intervention group
Group type: COMPARATOR
Intervention: FPANS 200 micrograms once daily (od)
Number of subjects: 549
Study 2790419 — intervention group
Group type: EXPERIMENTAL
Intervention: 99Tcm‐nanocolloid scintigraphy
Number of subjects: 19
Study 2790419 — intervention group
Group type: COMPARATOR
Intervention: Conventional skeletal scintigraphy
Number of subjects: 19
Study 2790419 — intervention group
Group type: COMPARATOR
Intervention: 99Tcm‐HMDP two-phase bone scintigraphy
Number of subjects: 19
Study 1071608 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic treatment with metolazone or hydrochlorothiazide
Number of subjects: 26
Study 1071608 — intervention group
Group type: COMPARATOR
Intervention: Control period (before treatment)
Number of subjects: 26
Study 30474376 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel church-based intervention including sermons, educational handouts, vegetable and fruit gardens, cooking and nutrition classes, daily mobile messaging, community mapping, and policy changes over 5 months.
Number of subjects: 268
Study 30474376 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly detailed in the abstract).
Number of subjects: 268
Study 28546097 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (long-term group)
Number of subjects: 7808
Study 28546097 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (crossover group)
Number of subjects: 7808
Study 28546097 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg subcutaneous every 6 months for 3 years (both groups)
Number of subjects: 7808
Study 28546097 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 years (control group)
Number of subjects: 7808
Study 24897394 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin administered after placenta separation (Group 1)
Number of subjects: 178
Study 24897394 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin administered after delivery of the shoulder (Group 2)
Number of subjects: 178
Study 23939510 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care depression management
Number of subjects: 205
Study 23939510 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 205
Study 21570033 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic vertical traction
Number of subjects: 98
Study 21570033 — intervention group
Group type: COMPARATOR
Intervention: Land-based supine flexion
Number of subjects: 98
Study 19575235 — intervention group
Group type: EXPERIMENTAL
Intervention: Toltrazuril (Baycox 5% suspension)
Number of subjects: 145
Study 19575235 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclazuril
Number of subjects: 145
Study 19575235 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 145
Study 18396608 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-packaging antimalarial drugs and counselling
Number of subjects: 436
Study 18396608 — intervention group
Group type: COMPARATOR
Intervention: Counselling but no pre-packaging (Control group A)
Number of subjects: 436
Study 18396608 — intervention group
Group type: COMPARATOR
Intervention: Neither counselling nor pre-packaging (Control group B)
Number of subjects: 436
Study 12782973 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual endplay assessment with spinal manipulation
Number of subjects: 104
Study 12782973 — intervention group
Group type: COMPARATOR
Intervention: Sham manipulation (control group)
Number of subjects: 104
Study 11798728 — intervention group
Group type: EXPERIMENTAL
Intervention: H(2) strain vaccine
Number of subjects: 12036
Study 11798728 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12036
Study 9371077 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal remedies
Number of subjects: 0
Study 7950211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CTX) and Traditional Chinese Medicine (TCM)
Number of subjects: 41
Study 7950211 — intervention group
Group type: COMPARATOR
Intervention: Control group with same western medicine but no TCM
Number of subjects: 41
Study 2906458 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 75 mg twice daily
Number of subjects: 0
Study 2906458 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 150 mg at bedtime
Number of subjects: 0
Study 2906458 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxatidine acetate, 150 mg after evening meal
Number of subjects: 0
Study 28857576 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (Mindtastic Body Dissatisfaction app) with a brief counseling session and 14 days of training
Number of subjects: 53
Study 28857576 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention (Mindtastic Body Dissatisfaction app)
Number of subjects: 53
Study 28857576 — intervention group
Group type: COMPARATOR
Intervention: Wait list group (control)
Number of subjects: 53
Study 25837277 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhodiola rosea
Number of subjects: 57
Study 25837277 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 57
Study 25837277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 25837277 — intervention group
Group type: COMPARATOR
Intervention: Sertraline vs Placebo
Number of subjects: 57
Study 25837277 — intervention group
Group type: COMPARATOR
Intervention: Rhodiola rosea vs Placebo
Number of subjects: 57
Study 25837277 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 57
Study 23295630 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term supportive psychodynamic therapy (PDT)
Number of subjects: 103
Study 23295630 — intervention group
Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 103
Study 23295630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (PDT + Antidepressants)
Number of subjects: 103
Study 21481164 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 134
Study 21481164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 19221060 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D ultrasonography (US) enhanced with a perflubutane microbubble contrast agent
Number of subjects: 139
Study 19221060 — intervention group
Group type: COMPARATOR
Intervention: 3D contrast-enhanced multidetector CT
Number of subjects: 139
Study 16536197 — intervention group
Group type: EXPERIMENTAL
Intervention: Prime & Bond NT (Dentsply)
Number of subjects: 15
Study 16536197 — intervention group
Group type: COMPARATOR
Intervention: 37% phosphoric acid + Prime & Bond NT
Number of subjects: 15
Study 16536197 — intervention group
Group type: COMPARATOR
Intervention: Non-Rinse Conditioner (Dentsply) + Prime & Bond NT
Number of subjects: 15
Study 16536197 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Rinse Conditioner (Dentsply) + Prime & Bond 2.1 (Dentsply)
Number of subjects: 15
Study 16536197 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (3M ESPE)
Number of subjects: 15
Study 12485381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum voluntary clench (MVC) with a single 200-microm occlusal interference positioned on teeth 16, 13, 23, 26
Number of subjects: 30
Study 12485381 — intervention group
Group type: COMPARATOR
Intervention: MVC in intercuspal position
Number of subjects: 30
Study 10690389 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole abdominal radiotherapy 2.250 rads in ten fractions
Number of subjects: 257
Study 10690389 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan 8 mg/m2/d x 4 weeks x 18 courses
Number of subjects: 257
Study 10690389 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chromic phosphate 10‐20 mCi
Number of subjects: 257
Study 10690389 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 257
Study 9505838 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 weighted fat suppressed turbo spin echo (T2W SPIR)
Number of subjects: 36
Study 9505838 — intervention group
Group type: COMPARATOR
Intervention: Gadolinium-enhanced T1 weighted spin echo (Gd-T1W SE)
Number of subjects: 36
Study 8438599 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) and Molsidomine (ML)
Number of subjects: 20
Study 3887254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of trimethoprim
Number of subjects: 4
Study 3887254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of co-trimoxazole
Number of subjects: 4
Study 3887254 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of amoxycillin
Number of subjects: 4
Study 3887254 — intervention group
Group type: COMPARATOR
Intervention: Five-day course of trimethoprim
Number of subjects: 4
Study 31076331 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional fully crossed design for four noise reduction methods
Number of subjects: 10
Study 31076331 — intervention group
Group type: COMPARATOR
Intervention: Pseudoreader design using paired reader performances
Number of subjects: 10
Study 29762737 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal lifestyle intervention program (1-hour educational program, 3-month referral to Slimming World, pedometer, structured telephone and text support)
Number of subjects: 60
Study 29762737 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 29762737 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal lifestyle intervention program
Number of subjects: 60
Study 26725450 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vaccine (5×10^10 viral particles)
Number of subjects: 120
Study 26725450 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vaccine (2.5×10^10 viral particles)
Number of subjects: 120
Study 26725450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 24431901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of autologous bone marrow-derived mesenchymal stem cells (MSCs)
Number of subjects: 80
Study 24431901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 23291996 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory weight-loss program
Number of subjects: 24
Study 21406629 — intervention group
Group type: EXPERIMENTAL
Intervention: 320‐detector CT
Number of subjects: 154
Study 21406629 — intervention group
Group type: COMPARATOR
Intervention: 64‐detector CT
Number of subjects: 154
Study 21406629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study 18251758 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 0.1 mg imidafenacin
Number of subjects: 14
Study 18251758 — intervention group
Group type: COMPARATOR
Intervention: Intravenous infusion of 0.028 mg imidafenacin
Number of subjects: 14
Study 16855626 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 6066
Study 16855626 — intervention group
Group type: EXPERIMENTAL
Intervention: Two classes of antihypertensive medication
Number of subjects: 6066
Study 16855626 — intervention group
Group type: EXPERIMENTAL
Intervention: Three or more classes of antihypertensive medication
Number of subjects: 6066
Study 16855626 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor diagnosis of hypertension and taking antihypertensive medication
Number of subjects: 6066
Study 12826782 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol
Number of subjects: 1292
Study 12826782 — intervention group
Group type: EXPERIMENTAL
Intervention: prazosin
Number of subjects: 1292
Study 12826782 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide, diltiazem-SR, captopril, clonidine, prazosin
Number of subjects: 1292
Study 12826782 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1292
Study 10389204 — intervention group
Group type: EXPERIMENTAL
Intervention: Point of Care Testing (POCT)
Number of subjects: 0
Study 10389204 — intervention group
Group type: COMPARATOR
Intervention: Laboratory Testing
Number of subjects: 0
Study 9082840 — intervention group
Group type: EXPERIMENTAL
Intervention: Innogem (300 mg)
Number of subjects: 19
Study 9082840 — intervention group
Group type: COMPARATOR
Intervention: Lopid (300 mg)
Number of subjects: 19
Study 1900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (100 mg over 3 hours, group A)
Number of subjects: 223
Study 1900977 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical treatment (group B)
Number of subjects: 223
Study 1900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary arteriography in patients with a patent infarct‐related artery
Number of subjects: 223
Study 1900977 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary arteriography in patients with an occluded infarct‐related artery
Number of subjects: 223
Study 7011469 — intervention group
Group type: EXPERIMENTAL
Intervention: sulpiride (600-1,800 mg/day)
Number of subjects: 38
Study 7011469 — intervention group
Group type: COMPARATOR
Intervention: trifluoperazine (15-45 mg/day)
Number of subjects: 38
Study 7011469 — intervention group
Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 38
Study 30718125 — intervention group
Group type: EXPERIMENTAL
Intervention: mAGIC intervention
Number of subjects: 104
Study 30718125 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study 28640076 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 36
Study 28640076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 25869815 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftopidil (75 mg once in the morning and placebo twice a day)
Number of subjects: 92
Study 25869815 — intervention group
Group type: COMPARATOR
Intervention: Flopropione (80 mg three times a day)
Number of subjects: 92
Study 24005170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic steroid injection (ITS)
Number of subjects: 103
Study 24005170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO)
Number of subjects: 103
Study 24005170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ITS and HBO
Number of subjects: 103
Study 24005170 — intervention group
Group type: COMPARATOR
Intervention: Control group (no salvage therapies)
Number of subjects: 103
Study 20601033 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial systemic treatment for cGVHD
Number of subjects: 116
Study 19372432 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming writing assignments
Number of subjects: 416
Study 17987458 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention using feminist pedagogical methods
Number of subjects: 0
Study 17987458 — intervention group
Group type: COMPARATOR
Intervention: Control group of women of similar age from the same community
Number of subjects: 0
Study 15037273 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with stenting (PCI, stenting)
Number of subjects: 102
Study 15037273 — intervention group
Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (surgery)
Number of subjects: 102
Study 11333843 — intervention group
Group type: COMPARATOR
Intervention: 12 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16
Study 11333843 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16
Study 11333843 — intervention group
Group type: EXPERIMENTAL
Intervention: 28 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16
Study 11333843 — intervention group
Group type: EXPERIMENTAL
Intervention: 36 mg x kg(‐1) x d(‐1) lysine intake
Number of subjects: 16
Study 9203720 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined schedule of OPV at birth and both OPV and IPV at 6, 10, and 14 weeks of age
Number of subjects: 1685
Study 9203720 — intervention group
Group type: COMPARATOR
Intervention: OPV at birth and at 6, 10, and 14 weeks of age
Number of subjects: 1685
Study 9203720 — intervention group
Group type: COMPARATOR
Intervention: Placebo at birth followed by IPV at 6, 10, and 14 weeks of age
Number of subjects: 1685
Study 7960503 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichoriboside
Number of subjects: 0
Study 7960503 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichosaccharide
Number of subjects: 0
Study 7960503 — intervention group
Group type: COMPARATOR
Intervention: Control (unaffected men)
Number of subjects: 0
Study 7960503 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichoriboside and Trichosaccharide
Number of subjects: 0
Study 3113290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine, 4 mg
Number of subjects: 6
Study 3113290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine, 0.15 mg
Number of subjects: 6
Study 3113290 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine, 0.3 mg
Number of subjects: 6
Study 31838223 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dlPFC
Number of subjects: 100
Study 31838223 — intervention group
Group type: COMPARATOR
Intervention: Cerebellar tDCS (anodal and cathodal)
Number of subjects: 100
Study 31838223 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 100
Study 31838223 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS of the dlPFC
Number of subjects: 100
Study 31838223 — intervention group
Group type: COMPARATOR
Intervention: Anodal tDCS of the cerebellum
Number of subjects: 100
Study 31838223 — intervention group
Group type: COMPARATOR
Intervention: Cathodal tDCS of the cerebellum
Number of subjects: 100
Study 29055883 — intervention group
Group type: EXPERIMENTAL
Intervention: Movement control injury prevention exercise programme
Number of subjects: 81
Study 29055883 — intervention group
Group type: COMPARATOR
Intervention: Normal practice exercises (control)
Number of subjects: 81
Study 27318048 — intervention group
Group type: EXPERIMENTAL
Intervention: High ligation and stripping with and without patch saphenoplasty
Number of subjects: 130
Study 27318048 — intervention group
Group type: EXPERIMENTAL
Intervention: DUS pattern (junctional, nonjunctional, mixed)
Number of subjects: 130
Study 27318048 — intervention group
Group type: EXPERIMENTAL
Intervention: DUS features
Number of subjects: 130
Study 27318048 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ultrasound recurrence
Number of subjects: 130
Study 26040543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (RG) - complex multi-method rehabilitation intervention including structured education, cognitive behavioral therapy (CBT), progressive individualized exercise, and peer support.
Number of subjects: 50
Study 26040543 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) - standard post-operative care for the first 3 months after LFS.
Number of subjects: 50
Study 26040543 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation group (RG) - secondary outcomes include Oswestry Disability Index (ODI) and physical function assessments (walking 50 yards, ascend/descend a flight of stairs).
Number of subjects: 50
Study 26040543 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) - secondary outcomes include Oswestry Disability Index (ODI) and physical function assessments (walking 50 yards, ascend/descend a flight of stairs).
Number of subjects: 50
Study 22987601 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV test (Hybrid Capture 2)
Number of subjects: 132298
Study 22987601 — intervention group
Group type: COMPARATOR
Intervention: Pap test
Number of subjects: 132298
Study 21087711 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-ON
Number of subjects: 610
Study 21087711 — intervention group
Group type: COMPARATOR
Intervention: CRT-OFF
Number of subjects: 610
Study 19138953 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 500
Study 19138953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 16189255 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot estradiol, 0.2 mg/month i.m. with GH 0.05 mg/kg daily
Number of subjects: 14
Study 16189255 — intervention group
Group type: COMPARATOR
Intervention: GH alone (control group)
Number of subjects: 14
Study 12970631 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 45
Study 12970631 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 45
Study 10658893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT, n = 30)
Number of subjects: 90
Study 10658893 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovation Promotion Program (IPP, n = 30)
Number of subjects: 90
Study 10658893 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (n = 30)
Number of subjects: 90
Study 8841871 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of allopurinol 18 hours and 400 mg of allopurinol orally 3 hours before surgery
Number of subjects: 52
Study 8841871 — intervention group
Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 52
Study 1632701 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral OK-432
Number of subjects: 970
Study 1632701 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 970
Study 1632701 — intervention group
Group type: COMPARATOR
Intervention: Intradermal OK-432
Number of subjects: 970